TL;DR
This case report introduces a novel combination therapy of anlotinib (a multi-target tyrosine kinase inhibitor) and celecoxib (a COX-2 inhibitor) for abdominal desmoid tumors. The treatment resulted in significant tumor reduction and complete pain relief in a patient, suggesting a promising new therapeutic avenue for this rare and challenging disease.
What Problem Does This Paper Address?
Desmoid tumors (DTs), also known as aggressive fibromatosis, are rare, locally invasive tumors characterized by fibroblast proliferation. While surgical resection is the primary treatment, recurrence rates are high. Existing treatments like endocrine therapy, radiotherapy, and chemotherapy have varying success rates, and targeted therapies have historically shown limited efficacy, often reserved as a last resort. There's a clear need for more effective and less toxic treatment options, especially for aggressive or recurrent cases, and a lack of established treatment protocols for abdominal desmoid tumors. This paper addresses the challenge of finding a successful treatment for a patient with an aggressive abdominal desmoid tumor that had not responded well to previous interventions.
Methods
This paper presents a case report of a 50-year-old woman with an abdominal desmoid tumor. The treatment involved a combination of anlotinib and celecoxib. Anlotinib was administered orally at 10mg twice daily on days 1-14 of each 21-day cycle, and celecoxib was given at 0.1g twice daily. The treatment regimen was followed for 22 cycles. The study also includes a literature review to contextualize the findings within existing research on desmoid tumor treatments. Diagnostic methods included color Doppler ultrasound, enhanced CT scans, exploratory laparotomy with biopsy, and immunohistochemical staining. Tumor response was assessed using imaging (CT scans) and patient-reported pain scores (NRS).
Datasets
Not discussed in the paper. This is a case report and literature review, not a study involving large datasets for training or evaluation.
Key Insights and Ideas
- Synergistic Potential of Anlotinib and NSAIDs: The most significant insight is the apparent synergistic effect of combining anlotinib (a tyrosine kinase inhibitor targeting angiogenesis and tumor growth) with celecoxib (a COX-2 inhibitor, a type of NSAID). This combination appears to be more effective than either agent alone for desmoid tumors.
- Pain Management Breakthrough: The complete resolution of pain symptoms, alongside tumor reduction, highlights the potential of this combination therapy not just for tumor control but also for improving patient quality of life, a critical aspect in managing desmoid tumors.
- Targeted Therapy Evolution: The paper underscores the evolving landscape of targeted therapies for desmoid tumors, moving beyond older agents to newer drugs like anlotinib, which show promise.
- Abdominal DTs as a Specific Challenge: The focus on an abdominal desmoid tumor highlights a specific anatomical location that can present unique challenges in treatment and management.
Key Results
- Tumor Response: The patient achieved a partial response (PR) in tumor size, as evidenced by CT scans showing significant reduction.
- Pain Relief: The patient's pain symptoms completely disappeared, with the Numerical Rating Scale (NRS) score dropping to 0.
- Progression-Free Survival (PFS): The patient's tumor was significantly reduced, and the progression-free survival exceeded 18 months at the time of reporting.
- Toxicity: The treatment was associated with mild toxicity.
- Treatment Duration: The patient received 22 cycles of the combined anlotinib and celecoxib regimen.
Limitations and Future Work
- Single Case Report: The primary limitation is that these findings are based on a single patient. This limits the generalizability of the results.
- Need for Larger Studies: The authors emphasize the need for larger, prospective studies to confirm the efficacy and safety of this combination therapy for desmoid tumors.
- Optimal Dosing: While a specific dosage was used, the optimal combination dose for anlotinib and NSAIDs requires further exploration.
- Long-Term Outcomes: The long-term efficacy and safety profile of this combination therapy remain to be fully determined.
- Mechanism Exploration: Further research into the precise mechanisms by which anlotinib and NSAIDs interact to treat desmoid tumors is warranted.
- Quality of Life Assessment: While pain was addressed, future studies should incorporate comprehensive health-related quality of life (HRQOL) assessments.
Summary updated